| 12337038 |
Conjugates comprising cleavable beta-glucuronide-containing linkers |
Akbar Husain Khan, Maximillian Taro William Lee, Mattia COCCO, Boliang Deng, Jonathan David BEADLE +5 more |
2025-06-24 |
|
| 12226490 |
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class |
Amandeep Gakhal, Abigail Yu, Ryan Stafford, Jeffrey Hanson, Alice Yam +8 more |
2025-02-18 |
|
| 12178876 |
Conjugates comprising cleavable linkers |
Akbar Husain Khan, Maximillian Taro William Lee, Nicole Danielle Bartolo, William Robert Fraser Goundry |
2024-12-31 |
$209,260,000 |
| 12144869 |
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates |
Amandeep Gakhal, Abigail Yu, Ryan Stafford, Jeffrey Hanson, Alice Yam +8 more |
2024-11-19 |
$4,686,000 |
| 11744876 |
Immunomodulator antibody drug conjugates and uses thereof |
Alice Yam, Cristina Abrahams, Willy Solis, Xiaofan LI, Ryan Stafford +4 more |
2023-09-05 |
$3,731,000 |
| 11365263 |
Bifunctional cytotoxic agents containing the CTI pharmacophore |
Chakrapani Subramanyam, Lawrence Nathan Tumey, Zecheng Chen, Jeffrey M. Casavant |
2022-06-21 |
$765,172,000 |
| 10968242 |
Cyclopentane-based modulators of STING (stimulator of interferon genes) |
Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Mehran Jalaie +1 more |
2021-04-06 |
$415,547,000 |
| 10870706 |
Bifunctional cytotoxic agents containing the CTI pharmacophore |
Chakrapani Subramanyam, Lawrence Nathan Tumey, Zecheng Chen, Jeffrey M. Casavant |
2020-12-22 |
$1,465,258,000 |
| 10662204 |
Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents |
Simon Paul Planken, Hengmiao Cheng, Michael Raymond Collins, Jillian Elyse SPANGLER, Alexei Brooun +4 more |
2020-05-26 |
$392,214,000 |
| 10590115 |
Tetrahydroquinazoline derivatives useful as anticancer agents |
Simon Paul Planken, Hengmiao Cheng, Michael Raymond Collins, Jillian Elyse SPANGLER, Alexei Brooun +4 more |
2020-03-17 |
$194,251,000 |
| 10544095 |
3-indol substituted derivatives, pharmaceutical compositions and methods for use |
Sacha Ninkovic, Michael Raymond Collins, Stefano Crosignani, Indrawan James McAlpine, Stephanie Anne Scales +1 more |
2020-01-28 |
$176,069,000 |
| 10538542 |
Cyclopentane-based modulators of STING (stimulator of interferon genes) |
Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome +2 more |
2020-01-21 |
$463,851,000 |
| 10391182 |
Bifunctional cytotoxic agents |
Matthew David Doroski, Zecheng Chen, Hud Lawrence Risley, Jeffrey M. Casavant, Christopher John O'Donnell +2 more |
2019-08-27 |
$278,016,000 |
| 10086085 |
Bifunctional cytotoxic agents |
Matthew David Doroski, Zecheng Chen, Hud Lawrence Risley, Jeffrey M. Casavant, Christopher John O'Donnell +2 more |
2018-10-02 |
$866,888,000 |
| 9873690 |
3-indol substituted derivatives, pharmaceutical compositions and methods for use |
Sacha Ninkovic, Stefano Crosignani, Indrawan James McAlpine, Michael Raymond Collins, Stephanie Anne Scales +1 more |
2018-01-23 |
$117,720,000 |
| 9296686 |
Preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide |
Jean-Michel Vernier |
2016-03-29 |
|
| 9249186 |
Cytotoxic peptides and antibody drug conjugates thereof |
Matthew David Doroski, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell Dushin +2 more |
2016-02-02 |
$195,231,000 |
| 9138486 |
Cytotoxic peptides and antibody drug conjugates thereof |
Matthew David Doroski, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell Dushin +2 more |
2015-09-22 |
$161,915,000 |
| 8884058 |
Preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide |
Jean-Michel Vernier |
2014-11-11 |
|
| 8828401 |
Cytotoxic peptides and antibody drug conjugates thereof |
Matthew David Doroski, Christopher John O'Donnell, Chakrapani Subramanyam, Beth Vetelino, Russell Dushin +2 more |
2014-09-09 |
$296,433,000 |
| 8829052 |
Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK |
Jean-Michel Vernier, Dinesh Barawkar, Varaprasad Chamakura, Hassan El Abdellaoul, Zhi Hong |
2014-09-09 |
|
| 8513443 |
Preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-3,4-difluoro-2(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide |
Jean-Michel Vernier |
2013-08-20 |
|
| 8101799 |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
Jean-Michel Vernier, Dinesh Barawkar, Varaprasad Chamakura, Hassan El Abdellaoui, Zhi Hong |
2012-01-24 |
$4,673,000 |
| 8063049 |
Inhibitors of MEK |
Yung-hyo Koh, Zhi Hong, Jean-Michel Vernier |
2011-11-22 |
$4,278,000 |
| 7820664 |
Inhibitors of MEK |
Jean-Michel Vernier, Yung-hyo Koh, Zhi Hong |
2010-10-26 |
|
